Table 1 Baseline clinicopathological characteristics of patients harboring ROS1 fusions
| Â | All ROS1 fusion lung cancer patients (n = 447, n, %) | NGS identified ROS1 fusion lung cancer patients (n = 264, n, %) | Locally-advanced/advanced ROS1 fusion lung cancer patients (n = 235, n, %) | Crizotinib, n = 168 | Chemotherapy, n = 67 | p | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All (n = 168, n, %) | Single ROS1 fusion (n = 159) | Non-reciprocal/reciprocal ROS1 translocation (n = 9) | p | All (n = 67, n, %) | Single ROS1 fusion (n=61) | Non-reciprocal/reciprocal ROS1 translocation (n = 6) | p | |||||||||||
All (n = 159, n, %) | CD74-ROS1 (n = 90, n, %) | Non-CD74-ROS1 (n = 69, n, %) | p | All (n = 61, n, %) | CD74-ROS1 (n = 40, n, %) | Non-CD74-ROS1 (n = 21, n, %) | p | |||||||||||
Age (Median range) | 52 (25–79) | 52 (25–79) | 52 (25–79) | 52 (27–79) | 52 (27–79) | 52 (27–79) | 52 (29–79) | 0.868 | 54 (37–74) | 0.793 | 52 (27–79) | 53 (29–64) | 54 (26–72) | 54 (29–79) | 0.837 | 54 (42–58) | 0.889 | 0.837 |
Sex | Â | Â | Â | Â | Â | Â | Â | 0.443 | Â | 0.487 | Â | Â | Â | Â | Â | Â | 0.662 | 0.508 |
 Female | 293 (66) | 166 (63) | 147 (63) | 63(38) | 61(38) | 38 (42) | 23 (33) |  | 2 (2) |  | 25 (37) | 22 (36) | 17 (43) | 5 (24) | 0.331 | 3 (50) |  |  |
 Male | 154 (34) | 98 (37) | 88 (37) | 105(62) | 98(62) | 52 (58) | 46 (67) |  | 7 (98) |  | 42 (63) | 39 (64) | 23 (57) | 16 (76) |  | 3 (50) |  |  |
Clinical stage | Â | Â | Â | Â | Â | Â | Â | 0.474 | Â | 0.535 | Â | Â | Â | Â | 0.215 | Â | 0.395 | 0.519 |
 III | 30 (7) | 23 (9) | 14 (6) | 10(6) | 9(6) | 4 (4) | 5 (7) |  | 1 (1) |  | 4 (6) | 3 (5) | 3 (8) | 0 (0) |  | 1 (16.7) |  |  |
 IIIa | 0 (0) | 0 (0) | 0 (0) | 0(0) | 0(0) | 0 (0) | 0 (0) |  | 0 (0) |  | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  | 0 (0) |  |  |
 IIIb | 9 (2) | 5 (2) | 2 (1) | 2(1) | 1(1) | 1 (1) | 0 (0) |  | 0 (0) |  | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  | 0 (0) |  |  |
 IIIc | 21 (5) | 18 (7) | 12 (5) | 8(5) | 8(5) | 3 (3) | 5 (7) |  | 1 (1) |  | 4 (6) | 3 (5) | 3 (8) | 0 (0) |  | 1 (16.7) |  |  |
 IV | 417 (93) | 241 (91) | 221 (94) | 158(94) | 150(94) | 86 (96) | 64 (93) |  | 8 (99) |  | 63 (94) | 58 (95) | 37 (92) | 21 (100) |  | 5 (83.3) |  |  |
Smoking status | Â | Â | Â | Â | Â | Â | Â | 0.284 | Â | 0.487 | Â | Â | Â | Â | 0.33 | Â | 0.933 | Â |
 Smoker or former smoker | 89 (20) | 62 (23) | 54 (23) | 32(19) | 29(18) | 19 (21) | 10 (14) |  | 2 (2) |  | 8 (12) | 6 (10) | 5 (13) | 1 (5) |  | 0 (0) |  |  |
 Nonsmoker | 358 (80) | 202 (77) | 181 (77) | 136(81) | 130(82) | 71 (79) | 59 (86) |  | 7 (98) |  | 59 (88) | 55 (90) | 35 (87) | 20 (95) |  | 6 (100) |  |  |
ECOG PS score | Â | Â | Â | Â | Â | Â | Â | 0.943 | Â | 0.938 | Â | Â | Â | Â | 0.893 | Â | 0.933 | 0.697 |
 0–1 | 430 (96) | 253 (96) | 226 (96) | 162(96) | 153(96) | 86 (96) | 67 (97) |  | 9 (100) |  | 64 (96) | 58 (95) | 38 (95) | 20 (95) |  | 6 (100) |  |  |
 ≥ 2 | 17 (4) | 11 (4) | 9 (4) | 6(4) | 6(4) | 4 (4) | 2 (3) |  | 0 (0) |  | 3 (4) | 3 (5) | 2 (5) | 1 (5) |  | 0 (0) |  |  |
Tumor histology | Â | Â | Â | Â | Â | Â | Â | 0.998 | Â | 0.974 | Â | Â | Â | Â | / | Â | / | Â |
 Adenocarcinoma | 445 (99) | 262 (99) | 234 (99) | 166(99) | 157(99) | 89 (99) | 68 (99) |  | 9 (100) |  | 67 (100) | 61 (100) | 40(100) | 21 (100) |  | 6(100) |  |  |
 Squamous cell carcinoma | 2 (1) | 2 (1) | 1 (1) | 2 (1) | 2 (1) | 1 (1) | 1 (1) |  | 0 (0) |  | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  | 0 (0) |  |  |
Presence of brain metastasis at baseline | Â | Â | Â | Â | Â | Â | Â | 0.83 | Â | 0.735 | Â | Â | Â | Â | 0.928 | Â | 0.666 | 0.747 |
 Present | 129 (29) | 69 (26) | 58 (25) | 45 (27) | 42 (26) | 23 (26) | 19 (28) |  | 3 (33) |  | 16 (24) | 14 (23) | 9 (23) | 5 (24) |  | 2 (33.3) |  |  |
 Absent | 318 (71) | 195 (74) | 177 (75) | 123 (73) | 117 (74) | 67 (74) | 53 (72) |  | 6 (67) |  | 51 (76) | 47 (77) | 31 (77) | 16 (76) |  | 4 (66.7) |  |  |
Method used for evaluating brain metastasis | Â | Â | Â | Â | Â | Â | Â | 0.129 | Â | 0.474 | Â | Â | Â | Â | 0.924 | Â | 0.845 | 0.796 |
 CT | 169 (38) | 98 (37) | 86 (37) | 64 (38) | 62 (39) | 42 (47) | 20 (29) |  | 2 (22) |  | 26 (39) | 24 (39) | 16 (40) | 8 (38) |  | 2 (33.3) |  |  |
 MRI | 278 (62) | 166 (63) | 149 (63) | 104 (62) | 97 (61) | 48 (53) | 49 (71) |  | 7 (78) |  | 41 (61) | 37 (61) | 24 (60) | 13 (62) |  | 4 (66.7) |  |  |
Local therapy received for management of brain metastasis | Â | Â | Â | Â | Â | Â | Â | 0.938 | Â | 0.949 | Â | Â | Â | Â | 0.784 | Â | 0.833 | 0.603 |
 None | 89 (69) | 50 (72) | 44 (76) | 31 (69) | 29 (69) | 15 (65) | 14 (74) |  | 2 (67) |  | 11 (69) | 10 (71) | 7 (78) | 3 (60) |  | 5 (83.3) |  |  |
 WBRT | 22 (17) | 10 (14) | 8 (14) | 8 (18) | 7 (17) | 5 (22) | 2 (11) |  | 1 (33) |  | 2 (13) | 1 (7) | 1 (11) | 0 (0) |  | 1 (16.7) |  |  |
 SBRT | 18 (14) | 9 (14) | 6 (10) | 6 (13) | 6 (14) | 3 (13) | 3 (15) |  | 0 (0) |  | 3 (18) | 3 (22) | 1 (11) | 2 (40) |  | 0 (0) |  |  |
Disease status | Â | Â | Â | Â | Â | Â | Â | 0.974 | Â | 0.176 | Â | Â | Â | Â | 0.215 | Â | 0.296 | 0.387 |
 Non-progression | 232 (52) | 146 (55) | 124 (53) | 57 (34) | 51 (32) | 29 (32) | 22 (32) |  | 6 (67) |  | 4 (6) | 4 (7) | 3 (8) | 1 (5) |  | 0 (0) |  |  |
 Progression | 215 (48) | 118 (45) | 111 (47) | 111 (66) | 108 (68) | 61 (68) | 47 (68) |  | 3 (33) |  | 63 (94) | 57 (93) | 37 (92) | 20 (95) |  | 6 (100) |  |  |
Site of progression | Â | Â | Â | Â | Â | Â | Â | 0.679 | Â | 0.819 | Â | Â | Â | Â | 0.949 | Â | 0.835 | 0.849 |
 Brain | 93 (43) | 53 (45) | 48 (43) | 48 (43) | 47 (44) | 25 (41) | 22 (47) |  | 1 (33) |  | 19 (30) | 17 (30) | 11 (30) | 6 (30) |  | 2 (33.3) |  |  |
 Non-brain | 122 (57) | 65 (55) | 63 (57) | 63 (57) | 61 (56) | 36 (59) | 25 (53) |  | 2 (67) |  | 44 (70) | 40 (70) | 26 (70) | 14 (70) |  | 4 (66.7) |  |  |